ARAVIVE (ARAV) Stock Price, News & Analysis

Company Overview

Aravive, Inc. is a clinical-stage biopharmaceutical company focused on the development of innovative therapies that address mechanisms of tumor progression and treatment resistance. The company’s lead product candidate, AVB-500, is a high-affinity soluble receptor decoy designed to neutralize growth arrest-specific 6 (Gas6) and inhibit signaling through the Axl receptor tyrosine kinase. By targeting the Gas6/Axl pathway, Aravive aims to enhance the effectiveness of existing therapies and overcome resistance in oncology indications.

AVB-500 is currently being evaluated in multiple Phase 2 clinical studies, including trials in platinum-resistant ovarian cancer and metastatic renal cell carcinoma, where it is administered in combination with standard-of-care treatments. In addition to its oncology programs, Aravive is exploring the role of Gas6/Axl signaling in fibrotic diseases, leveraging translational biomarkers and strategic collaborations to advance its preclinical candidates. The company’s development strategy emphasizes rigorous clinical design and partnerships to expedite the path to potential regulatory approval.

Founded in 2015 and headquartered in Houston, Texas, Aravive operates clinical trial sites across North America and Europe. The company is led by Chief Executive Officer R. Joseph Eustace, whose experience in oncology drug development is complemented by a leadership team with deep expertise in translational science, clinical operations and regulatory affairs. Together, Aravive’s management is dedicated to translating novel scientific insights into therapeutic solutions for patients with high unmet needs.

Key Stats

• Today's Range: $0.04 to $0.04
• 50-Day Range: $0.04 to $0.04
• 52-Week Range: $0.04 to $2.46
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ARAV Stock Analysis - Frequently Asked Questions

How have ARAV shares performed this year?

ARAVIVE's stock was trading at $0.0401 on January 1st, 2025. Since then, ARAV shares have increased by 0.0% and is now trading at $0.0401.

How were ARAVIVE's earnings last quarter?

ARAVIVE, INC (NASDAQ:ARAV) posted its earnings results on Wednesday, October, 27th. The company reported ($0.53) EPS for the quarter, missing analysts' consensus estimates of ($0.46) by $0.07. The company had revenue of $2.41 million for the quarter, compared to analysts' expectations of $2.36 million.

How do I buy shares of ARAVIVE?

Shares of ARAV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of ARAVIVE own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ARAVIVE investors own include NVIDIA (NVDA), CymaBay Therapeutics (CBAY), Broadcom (AVGO), GE Aerospace (GE), Advanced Micro Devices (AMD), CrowdStrike (CRWD) and Meta Platforms (META).

Company Calendar

• Last Earnings: 10/27/2021
• Today: 9/10/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ARAV
• CIK: 1513818
• Web: www.aravive.com
• Phone: (936) 355-1910
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $9.14 million
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: No Data
• Beta: N/A